Its because they haven't included the likely profits from being closely involved in the Oxford vaccine in FY 21 forward estimates. They have included the costs only.
Otherwise you are correct in noticing that the headline results do not indicate a company priced for growth.
Ann: CSL Results Announcement, page-63
-
- There are more pages in this discussion • 59 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add CSL (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$285.54 |
Change
-1.120(0.39%) |
Mkt cap ! $137.3B | |||
| Open | High | Low | Value | Volume |
| $285.50 | $285.86 | $282.18 | $110.7M | 388.8K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 2 | 368 | $285.31 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $285.54 | 425 | 1 |
View Market Depth
| Last trade - 16.10pm 13/11/2024 (20 minute delay) ? |
| CSL (ASX) Chart |